Unveiling Preclinical Characterization of XB371, a Novel Anti-Tissue Factor ADC

  • Introducing XB371 design as a novel belotecan ADC, created with the SMARTag ADC design platform
  • Laying out a demonstration of in vitro bystander and ICD activity
  • Demonstrating XB371’s potent, cytotoxic activity in TF-expressing CDX and PDX preclinical models